SG Americas Securities LLC lowered its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) by 73.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,450 shares of the company’s stock after selling 23,760 shares during the quarter. SG Americas Securities LLC’s holdings in Axsome Therapeutics were worth $324,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Axsome Therapeutics by 27.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,827 shares of the company’s stock worth $158,000 after purchasing an additional 831 shares during the last quarter. Kestra Advisory Services LLC increased its position in shares of Axsome Therapeutics by 53.4% during the first quarter. Kestra Advisory Services LLC now owns 9,595 shares of the company’s stock worth $397,000 after purchasing an additional 3,341 shares in the last quarter. Peregrine Capital Management LLC grew its position in Axsome Therapeutics by 38.9% during the 1st quarter. Peregrine Capital Management LLC now owns 165,656 shares of the company’s stock worth $6,857,000 after purchasing an additional 46,358 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Axsome Therapeutics by 10.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,350 shares of the company’s stock valued at $574,000 after acquiring an additional 1,300 shares during the period. Finally, Financial Consulate Inc. purchased a new stake in Axsome Therapeutics in the first quarter valued at approximately $201,000. Institutional investors own 54.96% of the company’s stock.
Axsome Therapeutics Price Performance
Axsome Therapeutics stock opened at $56.82 on Tuesday. Axsome Therapeutics, Inc. has a 12 month low of $20.63 and a 12 month high of $71.98. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -14.49 and a beta of 1.75. The company has a current ratio of 2.44, a quick ratio of 2.20 and a debt-to-equity ratio of 6.15. The business’s 50 day simple moving average is $51.42 and its 200 day simple moving average is $41.82.
Analyst Ratings Changes
Several research analysts recently weighed in on AXSM shares. Jefferies Financial Group reduced their price target on Axsome Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, September 30th. Cantor Fitzgerald cut their price objective on shares of Axsome Therapeutics from $64.00 to $54.00 in a research report on Wednesday, August 10th. Morgan Stanley raised their price objective on shares of Axsome Therapeutics from $71.00 to $74.00 and gave the company an “equal weight” rating in a research note on Friday, October 14th. Loop Capital initiated coverage on shares of Axsome Therapeutics in a research note on Tuesday, November 1st. They issued a “buy” rating and a $95.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $210.00 price target on shares of Axsome Therapeutics in a report on Tuesday, October 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $104.64.
Axsome Therapeutics Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- 3 Reasons Another Shoe May Drop for Skechers
- Is Clothier V.F. Corporation’s 7% Dividend Worth Trying On?
- Bulls Vs Bears: Mullen Automotive Short Interest Grows
- Palantir Falls Into The Hands Of Value Investors
- The Analysts Can’t Keep Up with Arista Networks Stock
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.